Impressive Sales Performance for DARZALEX®
In a notable announcement, Genmab A/S (NASDAQ: GMAB) reported significant net sales figures for its flagship product, DARZALEX® (daratumumab), in the second quarter of 2025. The company's net sales for this period soared to USD 3,539 million, reflecting a strong performance in the pharmaceutical market.
Breakdown of Sales
Genmab’s reported sales indicate that the U.S. market contributed USD 2,017 million, while international markets accounted for USD 1,521 million. The success of DARZALEX underscores the effective partnership between Genmab and its collaborator, Johnson & Johnson, allowing for effective development and commercialization strategies that have led to these impressive figures.
Collaboration with Johnson & Johnson
Under the exclusive license agreement, Genmab receives royalties from Johnson & Johnson, which includes the sales of both intravenous and subcutaneous formulations of DARZALEX. This partnership has allowed Genmab to expand its market reach and improve access to its innovative therapy for patients around the world.
Genmab's Innovative Approach
Genmab is dedicated to advancing cancer therapies through its innovative science and technology. With over 25 years of experience, the company’s commitment to research has resulted in a robust pipeline, enabling the development of cutting-edge antibody therapeutics. This ambition is fueled by a passionate team that embraces innovation, collaboration, and a solid understanding of patient needs in the oncology field.
Future Vision
With a clear vision aimed at revolutionizing cancer treatments, Genmab is focused on launching breakthrough therapies by 2030. The company is working diligently towards making significant strides in medical science, aiming to improve patient outcomes with exciting new antibody medicines.
Global Presence
Headquartered in Copenhagen, Denmark, Genmab has established a strong international presence across North America, Europe, and Asia Pacific. This global footprint enhances its ability to influence the market and deliver its therapeutic innovations effectively. As Genmab continues to grow, its commitment to advancing healthcare remains at the forefront of its corporate mission.
Contact Information
For further inquiries regarding Genmab, interested parties can reach out to Marisol Peron, Senior Vice President of Global Communications & Corporate Affairs, at +1 609 524 0065 or via email at mmp@genmab.com. Alternatively, Andrew Carlsen, Vice President, Head of Investor Relations, is available at +45 3377 9558 or acn@genmab.com.
Frequently Asked Questions
What is DARZALEX® used for?
DARZALEX® is an innovative medication used to treat multiple myeloma, a type of blood cancer. It works by targeting and eliminating myeloma cells.
Who manufactures DARZALEX®?
DARZALEX® is manufactured by Genmab A/S in collaboration with Johnson & Johnson, which manages the commercial distribution.
What were the total sales reported for the second quarter of 2025?
The total net sales of DARZALEX® for the second quarter of 2025 were USD 3,539 million.
What regions contributed to the sales figures?
The U.S. market contributed USD 2,017 million, while remaining global markets accounted for USD 1,521 million.
How can I learn more about Genmab’s products?
For more information about Genmab’s innovative therapies and ongoing research, you can visit Genmab.com.
